SCHEMBL26623686

SCHEMBL26623686

COC(=O)c1cc(S(=O)(=O)Cl)c(=O)n(C)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 1/20 0.40
BRD4 O60885 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.39
CYP1A2 P05177 4/20 0.39
CYP2C19 P33261 4/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2D6 P10635 1/20 0.39
CASP3 P42574 1/20 0.38
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
MAPK10 P53779 2/20 0.38
USP2 O75604 1/20 0.38
CYP3A4 P08684 1/20 0.36
STS P08842 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217732 0.78 CYP1A2 (0.46) ALDH1A1L3MBTL1MAPTBRD4SMN1; SMN2
SCHEMBL16486199 0.76 BRD4 (0.46) ALDH1A1MAPTBRD4SMN1; SMN2CYP1A2
SCHEMBL21384011 0.74 ALDH1A1 (0.45) ALDH1A1L3MBTL1MAPTBRD4SMN1; SMN2
SCHEMBL20945149 0.74 KDM4E (0.49) ALDH1A1MAPTBRD4SMN1; SMN2CYP1A2
SCHEMBL924584 0.74 ALDH1A1 (0.58) ALDH1A1L3MBTL1MAPTSMN1; SMN2CYP1A2
SCHEMBL30814624 0.73 SMN1; SMN2 (0.44) ALDH1A1L3MBTL1MAPTBRD4SMN1; SMN2
SCHEMBL22000137 0.72 ACLY (0.46) ALDH1A1L3MBTL1BRD4KDM4ETSHR
SCHEMBL10940459 0.72 CYP1A2 (0.46) ALDH1A1L3MBTL1MAPTSMN1; SMN2CYP1A2
SCHEMBL2175671 0.71 ALDH1A1 (0.43) ALDH1A1L3MBTL1BRD4SMN1; SMN2CYP1A2
SCHEMBL2175814 0.71 CPT2 (0.46) ALDH1A1L3MBTL1MAPTSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289793-A1 MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE ESPERION THERAPEUTICS, INC. 2025-09-18 US disclosed
EP-4519251-A1 MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE Esperion Therapeutics, Inc. (US) 2025-03-12 EP disclosed
CN-119137107-A Macrocyclic inhibitors of ATP citrate lyase 艾斯柏伦治疗公司 2024-12-13 CN disclosed
WO-2023215220-A1 MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE ESPERION THERAPEUTICS, INC. (US) 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289793-A1 MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE ACLY, CS, ATP5ME ALDH1A1 792/4885L3MBTL1 2585/4885MAPT 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.